Condition: Mild Cognitive Impairment · Sponsor: University of Colorado, Denver
This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.
This description comes directly from the study's public registry record.
Raeghan Mueller, PhD · 3037242210 · raeghan.mueller@cuanschutz.edu
Always discuss trial participation with your own doctor first.
| University of Colorado - Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05822362